Index -
P/E -
EPS (ttm) -1.92
Insider Own 26.27%
Shs Outstand 51.65M
Perf Week 11.98%
Market Cap 309.40M
Forward P/E -
EPS next Y -1.79
Insider Trans 0.00%
Shs Float 38.73M
Perf Month 20.20%
Income -82.44M
PEG -
EPS next Q -0.43
Inst Own 67.12%
Short Float 4.54%
Perf Quarter 103.10%
Sales 0.00M
P/S -
EPS this Y 8.95%
Inst Trans 0.10%
Short Ratio 2.73
Perf Half Y 208.38%
Book/sh 2.26
P/B 2.61
EPS next Y -4.49%
ROA -52.37%
Short Interest 1.76M
Perf Year 300.68%
Cash/sh 2.50
P/C 2.35
EPS next 5Y -
ROE -70.94%
52W Range 1.43 - 6.85
Perf YTD 109.61%
Dividend Est. -
P/FCF -
EPS past 5Y -49.79%
ROI -59.34%
52W High -14.01%
Beta 2.60
Dividend TTM -
Quick Ratio 6.82
Sales past 5Y 0.00%
Gross Margin -
52W Low 311.89%
ATR (14) 0.44
Dividend Ex-Date -
Current Ratio 6.82
EPS Y/Y TTM 23.34%
Oper. Margin 0.00%
RSI (14) 62.60
Volatility 8.39% 8.18%
Employees 54
Debt/Eq 0.22
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 12.80
Option/Short Yes / Yes
LT Debt/Eq 0.19
EPS Q/Q 35.12%
Payout -
Rel Volume 0.88
Prev Close 5.11
Sales Surprise -
EPS Surprise 27.04%
Sales Q/Q -
Earnings Mar 12 BMO
Avg Volume 644.93K
Price 5.89
SMA20 13.86%
SMA50 20.06%
SMA200 69.22%
Trades
Volume 566,432
Change 15.26%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-14-23 Initiated
Piper Sandler
Overweight
Jun-30-23 Upgrade
Stifel
Hold → Buy
$2 → $10
Jun-28-23 Upgrade
H.C. Wainwright
Neutral → Buy
$11
Jun-27-23 Upgrade
Wedbush
Neutral → Outperform
$10
Mar-29-22 Downgrade
Wedbush
Outperform → Neutral
Mar-22-22 Downgrade
H.C. Wainwright
Buy → Neutral
Sep-30-21 Initiated
Stifel
Hold
$10
Jan-07-21 Initiated
Wedbush
Outperform
$45
Nov-24-20 Initiated
Berenberg
Buy
$58
May-04-20 Initiated
H.C. Wainwright
Buy
$53
Feb-24-20 Initiated
JP Morgan
Overweight
$42
Feb-24-20 Initiated
Jefferies
Buy
Feb-24-20 Initiated
Cowen
Outperform
Feb-24-20 Initiated
Canaccord Genuity
Buy
$50
Show Previous Ratings
Apr-25-24 09:55AM
Apr-24-24 04:05PM
Apr-23-24 07:45AM
Apr-15-24 12:00PM
Apr-11-24 08:00AM
09:55AM
Loading…
Apr-08-24 09:55AM
Apr-07-24 06:00PM
Apr-03-24 08:00AM
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
(Associated Press Finance) -5.50%
08:00AM
Mar-05-24 04:30PM
Feb-28-24 08:00AM
Jan-04-24 08:00AM
07:00AM
Loading…
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
(Associated Press Finance)
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
Sep-18-23 12:34PM
(American City Business Journals)
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
(Associated Press Finance)
07:30AM
07:43AM
Loading…
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
07:30AM
Feb-27-23 08:00AM
Feb-15-23 05:46AM
Jan-19-23 05:41AM
Jan-05-23 08:00AM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-09-22 09:35AM
09:04AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-26-22 08:00AM
Sep-06-22 08:00AM
Aug-28-22 09:41AM
Aug-09-22 08:00AM
Aug-03-22 08:00AM
Aug-01-22 08:55AM
Jul-02-22 08:29AM
Jun-06-22 08:00AM
Jun-01-22 07:00AM
May-17-22 07:00AM
May-12-22 04:30PM
May-11-22 04:30PM
Apr-28-22 12:52PM
(American City Business Journals)
Apr-25-22 09:00AM
Apr-18-22 07:00AM
Apr-07-22 04:30PM
07:00AM
Mar-17-22 05:00PM
Mar-02-22 08:00AM
Feb-22-22 08:00AM
Feb-16-22 05:28AM
Jan-11-22 07:00AM
Jan-10-22 07:00AM
Jan-05-22 08:00AM
Nov-18-21 05:27AM
Nov-08-21 04:05PM
07:45AM
Oct-08-21 04:05PM
Oct-04-21 11:02AM
Sep-30-21 04:35PM
Sep-21-21 04:05PM
07:45AM
Aug-12-21 08:22AM
Aug-10-21 07:45AM
Aug-04-21 07:45AM
Aug-02-21 02:26AM
Jul-29-21 03:53PM
May-19-21 05:00PM
May-17-21 07:45AM
May-07-21 07:45AM
May-04-21 02:01AM
Apr-28-21 10:38AM
Apr-10-21 08:30AM
Mar-25-21 07:45AM
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BIOTECH GROWTH N V 10% Owner Oct 17 '23 Buy 2.34 400,000 934,080 8,517,839 Oct 19 03:08 PM Behbahani Ali Director Jul 05 '23 Buy 5.00 1,000,000 5,000,000 4,448,757 Jul 06 04:45 PM RA CAPITAL MANAGEMENT, L.P. Director Jul 05 '23 Buy 5.00 935,850 4,679,250 3,213,828 Jul 07 04:30 PM BIOTECH GROWTH N V 10% Owner Jun 30 '23 Buy 5.00 1,000,000 5,000,000 8,117,839 Jul 03 03:36 PM BIOTECH GROWTH N V 10% Owner Jun 27 '23 Buy 5.49 1,740,000 9,555,036 7,117,839 Jun 29 01:37 PM Epstein David M. SEE REMARKS Jun 27 '23 Sale 6.70 25,000 167,500 671,423 Jun 28 04:02 PM
Index -
P/E -
EPS (ttm) -1.97
Insider Own 5.21%
Shs Outstand 84.88M
Perf Week -2.07%
Market Cap 4.58B
Forward P/E -
EPS next Y -4.06
Insider Trans -3.49%
Shs Float 80.46M
Perf Month -23.16%
Income -153.61M
PEG -
EPS next Q -1.35
Inst Own 65.72%
Short Float 18.33%
Perf Quarter -11.64%
Sales 371.21M
P/S 12.33
EPS this Y -203.03%
Inst Trans -0.04%
Short Ratio 8.51
Perf Half Y 29.87%
Book/sh 23.52
P/B 2.29
EPS next Y 30.93%
ROA -6.87%
Short Interest 14.74M
Perf Year 9.06%
Cash/sh 19.95
P/C 2.70
EPS next 5Y -
ROE -8.17%
52W Range 37.55 - 91.10
Perf YTD -13.88%
Dividend Est. -
P/FCF -
EPS past 5Y 10.83%
ROI -7.29%
52W High -40.82%
Beta 1.79
Dividend TTM -
Quick Ratio 17.54
Sales past 5Y 33402.13%
Gross Margin 65.88%
52W Low 43.57%
ATR (14) 2.77
Dividend Ex-Date -
Current Ratio 17.54
EPS Y/Y TTM 76.72%
Oper. Margin -53.64%
RSI (14) 26.72
Volatility 4.22% 3.89%
Employees 407
Debt/Eq 0.13
Sales Y/Y TTM 30885.48%
Profit Margin -41.38%
Recom 2.21
Target Price 87.61
Option/Short Yes / Yes
LT Debt/Eq 0.12
EPS Q/Q 177.83%
Payout -
Rel Volume 0.78
Prev Close 53.73
Sales Surprise 42.76%
EPS Surprise 1559.13%
Sales Q/Q 3353333.33%
Earnings Feb 21 BMO
Avg Volume 1.73M
Price 53.91
SMA20 -11.14%
SMA50 -24.49%
SMA200 -9.50%
Trades
Volume 1,352,559
Change 0.34%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Dec-11-23 Downgrade
TD Cowen
Market Perform → Underperform
$30
Oct-17-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Sep-27-23 Initiated
Mizuho
Buy
$82
Aug-17-23 Upgrade
Citigroup
Neutral → Buy
May-30-23 Initiated
William Blair
Outperform
$75
Apr-13-23 Initiated
Cantor Fitzgerald
Overweight
$72
Mar-21-23 Initiated
Bernstein
Mkt Perform
$44
Mar-17-23 Initiated
Bryan Garnier
Buy
$70
Mar-07-23 Initiated
Robert W. Baird
Neutral
$46
Oct-11-22 Initiated
Morgan Stanley
Underweight
$37
Aug-09-22 Downgrade
Barclays
Overweight → Equal Weight
$99 → $88
Jun-23-22 Downgrade
Evercore ISI
Outperform → In-line
$66 → $60
Jun-17-22 Initiated
BMO Capital Markets
Outperform
$98
Apr-28-22 Initiated
Credit Suisse
Neutral
$78
Dec-07-21 Initiated
Cowen
Market Perform
Oct-19-21 Initiated
SVB Leerink
Outperform
$126
Jun-14-21 Upgrade
Citigroup
Sell → Neutral
$55 → $132
Apr-21-21 Upgrade
Jefferies
Hold → Buy
$172
Mar-04-21 Initiated
JMP Securities
Mkt Outperform
$160
Show Previous Ratings
Apr-26-24 05:50PM
Apr-25-24 07:00AM
Apr-22-24 06:00PM
04:30PM
12:49PM
10:31PM
Loading…
Apr-19-24 10:31PM
06:56AM
Apr-17-24 09:00AM
Apr-16-24 06:00PM
Apr-13-24 08:47AM
Apr-11-24 01:10PM
Apr-10-24 01:46PM
Apr-09-24 06:00PM
10:00AM
Apr-05-24 05:03AM
06:15PM
Loading…
Apr-04-24 06:15PM
Apr-03-24 08:00AM
Apr-01-24 08:00AM
Mar-30-24 06:50AM
Mar-28-24 08:39AM
Mar-27-24 04:50AM
Mar-25-24 06:15PM
Mar-24-24 10:08AM
Mar-23-24 06:45AM
Mar-22-24 11:30AM
Mar-21-24 04:19PM
Mar-20-24 01:49PM
Mar-19-24 06:15PM
12:07AM
Mar-17-24 08:50AM
08:45AM
Loading…
Mar-16-24 08:45AM
Mar-14-24 08:15AM
Mar-13-24 02:25PM
08:30AM
Mar-06-24 02:45PM
Mar-05-24 06:53PM
Mar-04-24 11:02AM
08:48AM
Feb-29-24 05:32PM
06:31AM
05:50AM
Feb-27-24 12:00PM
Feb-26-24 08:50AM
06:45AM
Feb-23-24 10:01AM
Feb-22-24 07:37AM
04:00AM
Feb-21-24 04:32PM
(Investor's Business Daily)
10:15AM
(Investor's Business Daily)
07:30AM
Feb-20-24 05:02AM
Feb-19-24 04:08PM
01:45AM
Feb-16-24 02:19PM
07:31AM
Feb-15-24 08:30AM
Feb-14-24 08:15AM
Feb-13-24 01:22PM
(Investor's Business Daily)
10:00AM
08:30AM
02:30AM
Feb-10-24 05:09PM
Feb-09-24 06:00PM
Feb-08-24 02:59AM
Feb-07-24 10:00AM
09:09AM
Feb-05-24 08:00AM
Feb-04-24 02:35PM
Feb-02-24 06:00PM
Feb-01-24 09:10PM
Jan-31-24 12:28PM
Jan-30-24 05:10AM
05:02AM
Jan-28-24 05:10AM
Jan-25-24 06:15PM
08:32AM
Jan-24-24 09:45AM
Jan-23-24 09:30AM
Jan-22-24 09:12AM
05:05AM
Jan-21-24 09:37AM
08:00AM
Jan-20-24 06:50AM
Jan-19-24 06:15PM
Jan-16-24 04:08PM
(Investor's Business Daily)
04:01PM
08:15AM
Jan-15-24 04:56PM
06:30AM
05:19AM
Jan-14-24 01:30PM
05:10AM
Jan-13-24 06:05AM
05:20AM
Jan-10-24 06:00AM
Jan-09-24 06:15PM
Jan-08-24 09:17AM
07:00AM
05:00AM
Jan-06-24 05:00AM
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kulkarni Samarth Chief Executive Officer Apr 15 '24 Option Exercise 19.12 19,582 374,408 227,704 Apr 17 05:45 PM Kulkarni Samarth Chief Executive Officer Apr 15 '24 Sale 59.91 19,582 1,173,232 208,122 Apr 17 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 15 '24 Option Exercise 19.12 20,000 382,400 228,122 Mar 18 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 15 '24 Sale 72.48 20,000 1,449,628 208,122 Mar 18 05:45 PM Prasad Raju Chief Financial Officer Mar 15 '24 Sale 72.69 3,524 256,160 6,476 Mar 18 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 12 '24 Sale 74.44 4,583 341,159 208,122 Mar 12 05:45 PM KASINGER JAMES R. General Counsel and Secretary Mar 12 '24 Sale 74.44 1,146 85,308 61,174 Mar 12 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 11 '24 Sale 78.26 9,802 767,105 203,705 Mar 12 05:45 PM KASINGER JAMES R. General Counsel and Secretary Mar 11 '24 Sale 78.26 2,801 219,206 60,070 Mar 12 05:45 PM Kulkarni Samarth Chief Executive Officer Feb 20 '24 Sale 79.67 6,370 507,498 194,257 Feb 21 05:45 PM KASINGER JAMES R. General Counsel and Secretary Feb 20 '24 Sale 79.67 1,913 152,409 57,371 Feb 21 05:45 PM Kulkarni Samarth Chief Executive Officer Feb 15 '24 Option Exercise 19.12 20,000 382,400 207,377 Feb 16 05:45 PM Kulkarni Samarth Chief Executive Officer Feb 15 '24 Sale 80.36 20,000 1,607,177 187,377 Feb 16 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 29 '24 Option Exercise 19.12 50,000 956,000 237,377 Jan 31 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 29 '24 Sale 60.51 50,000 3,025,573 187,377 Jan 31 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 16 '24 Option Exercise 19.12 20,000 382,400 207,377 Jan 18 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 16 '24 Sale 62.50 20,000 1,250,058 187,377 Jan 18 05:45 PM Kulkarni Samarth Chief Executive Officer May 30 '23 Option Exercise 19.12 25,000 478,000 412,377 Jun 01 05:44 PM Kulkarni Samarth Chief Executive Officer May 30 '23 Sale 64.88 25,000 1,621,894 387,377 Jun 01 05:44 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite